New trial
Phase I/II saruparib PARP1 inhibitor trial
- Trial ID
- NCT07060365 on ClinicalTrials.gov
- Cancer type
- Ovarian, Fallopian, or Primary Peritoneal Cancer
- Stage of research
- First-in-human
- Location
- 23 Locations
- Published in
- New in Oncology - July 25, 2025
This master protocol study, sponsored by AstraZeneca, evaluates novel biomarker-guided anticancer treatments in participants with advanced/recurrent ovarian, fallopian tube, or primary peritoneal cancer. In Substudy 1, treatment-naive patients with BRCA1/2 mutations receive oral saruparib—a PARP1 inhibitor small molecule—to assess safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy in a first-in-human setting.
More in ovarian cancer
-
Trial result · Oct 22, 2026 · NCT07213804
Sofetabart mipitecan (FRα-targeted ADC) posts 50.5% ORR and 8.1-mo mPFS in heavily pretreated HGOC—without keratopathy -
New trial · Oct 15, 2026 · NCT07851025
Phase 3 TREVI-OC-02 tests FRα-targeted torvutatug samrotecan plus bevacizumab maintenance in HRD-negative ovarian cancer -
New trial · Oct 15, 2026 · NCT07504588
Phase 2 NRG-GY038 compares sacituzumab govitecan plus bevacizumab with platinum-based treatment after PARP-inhibitor progression -
New trial · Oct 15, 2026 · NCT07776691
Phase 3 REJOICE-Ovarian04 tests CDH6-targeted raludotatug deruxtecan maintenance with or without bevacizumab -
New trial · Oct 8, 2026 · NCT07816666
Phase 3 torvutatug samrotecan FRα (FOLR1) ADC with exatecan (topoisomerase I) payload